Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis

Table 2

Three-month outcome of pediatric patients with mild-to-moderate ulcerative colitis according to the clinical disease activity index PUCAI and fecal calprotectin at baseline. The outcome was determined according to physicians global assessment.

No.	Disease activity according to the PUCAI (total score)	Calprotectin; µg/g of stool	Outcome within 3 months
1	Remission (<10)	14	Remission
2		14	Remission
3		16	Remission*
4		30	Remission
5		45	Remission
6		69	Remission
7		69	Remission
8		90	Remission
9		131	Remission
10		155	Flare (within two months)
11		189	Flare (when tapering corticoid)
12		333	Remission*
13		345	Flare
14		372	Remission
15		411	Remission
16		441	Remission
17		521	Remission
18		532	Flare (when tapering corticoid)
19		581	Remission
20		628	Remission
21		663	Flare (within a month)
22		796	Remission
23		902	Flare*
24		1052	Remission*
25		1173	Flare*
26		1233	Remission
27		1976	Flare (when tapering corticoid)
28		2295	Flare*
29		4518	Flare (within two weeks)
30		9625	Remission
31	Mild-to-moderate disease (10–64)	7	Remission
32		55	Remission
33		87	Remission
34		327	Flare (when tapering corticoid)
35		416	Remission
36		611	Lost from followup
37		653	Flare
38		751	Flare
39		766	Flare
40		829	Flare (ongoing)
41		856	Remission
42	Mild-to-moderate disease (10–34)	1067	Flare
43		1110	Remission
44		1127	Remission
45		1599	Flare (when tapering corticoid)
46		1667	Flare (within two weeks)
47		1911	Flare (ongoing)
48		2604	Flare
49		7287	Flare (when tapering corticoid)

 *Sample taken on the day of infliximab administration.